BriaCell Therapeutics Corp. (BCT.TO) Research

BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.

Market snapshot

Symbol
BCT.TO
Price
$4.11
Day change
0.00%
Market cap
$5.5M
P/E ratio
-0.24x
52-week range
3.68-42.8
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Rapid Dose Therapeutics Corp. (DOSE.CN)
  • Gemina Laboratories Ltd. (GLAB.CN)
  • Greenway Greenhouse Cannabis Corporation (GWAY.CN)
  • Hemostemix Inc. (HEM.V)
  • Izotropic Corporation (IZO.CN)
  • Microbix Biosystems Inc. (MBX.TO)
  • Pangenomic Health Inc. (NARA.CN)
  • Perimeter Medical Imaging AI, Inc. (PINK.V)

Open BriaCell Therapeutics Corp. (BCT.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.